Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Equus caballus | Ferritin light chain | Starlite/ChEMBL | No references |
Homo sapiens | lamin A/C | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Schistosoma mansoni | ferritin | Ferritin light chain | 175 aa | 171 aa | 44.4 % |
Schistosoma mansoni | ferritin | Ferritin light chain | 175 aa | 171 aa | 43.9 % |
Schistosoma mansoni | apoferritin-2 | Ferritin light chain | 175 aa | 142 aa | 29.6 % |
Echinococcus multilocularis | expressed protein | Ferritin light chain | 175 aa | 146 aa | 30.1 % |
Schistosoma japonicum | Ferritin, putative | Ferritin light chain | 175 aa | 144 aa | 24.3 % |
Echinococcus granulosus | expressed protein | Ferritin light chain | 175 aa | 146 aa | 28.8 % |
Schistosoma mansoni | apoferritin-2 | Ferritin light chain | 175 aa | 146 aa | 28.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | Intermediate filament tail domain containing protein | 0.0033 | 1 | 1 |
Loa Loa (eye worm) | cytoplasmic intermediate filament protein | 0.0017 | 0.1026 | 0.1026 |
Onchocerca volvulus | 0.0033 | 1 | 0.5 | |
Echinococcus multilocularis | musashi | 0.0033 | 1 | 1 |
Loa Loa (eye worm) | intermediate filament tail domain-containing protein | 0.0033 | 1 | 1 |
Schistosoma mansoni | intermediate filament proteins | 0.0033 | 1 | 0.5 |
Schistosoma mansoni | lamin | 0.0033 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0032 | 0.9646 | 0.9646 |
Schistosoma mansoni | lamin | 0.0033 | 1 | 0.5 |
Onchocerca volvulus | 0.0033 | 1 | 0.5 | |
Echinococcus granulosus | intermediate filament protein | 0.0033 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0033 | 1 | 1 |
Echinococcus multilocularis | lamin | 0.0033 | 1 | 1 |
Echinococcus multilocularis | lamin dm0 | 0.0033 | 1 | 1 |
Echinococcus granulosus | lamin | 0.0033 | 1 | 1 |
Loa Loa (eye worm) | intermediate filament protein | 0.0033 | 1 | 1 |
Echinococcus granulosus | lamin dm0 | 0.0033 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | = 0.1995 um | PUBCHEM_BIOASSAY: qHTS Assay for Modulators of Lamin A Splicing. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (binding) | = 0.7943 um | PUBCHEM_BIOASSAY: qHTS Assay for Identification of Novel General Anesthetics. In this assay, a GABAergic mimetic model system, apoferritin and a profluorescent 1-aminoanthracene ligand (1-AMA), was used to construct a competitive binding assay for identification of novel general anesthetics (Class of assay: confirmatory) [Related pubchem assays: 2385 (Probe Development Summary for Identification of Novel General Anesthetics), 2323 (Validation apoferritin assay run on SigmaAldrich LOPAC1280 collection)] | ChEMBL. | No reference |
Potency (functional) | 1.5849 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of binding or entry into cells for Lassa Virus. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID463114, AID540249] | ChEMBL. | No reference |
Potency (functional) | = 39.8107 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1). (Class of assay: confirmatory) [Related pubchem assays: 1030 (qHTS Validation Assay for Inhibitors of aldehyde dehydrogenase 1 (ALDH1A1))] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.